Entresto's patent war is back!

Recently, the patent competition surrounding Novartis' heavyweight Entresto can be described as a fierce battle, and there is a lot of gunpowder

On July 2, the website of the State Intellectual Property Office announced the invalidation of three patents, confirming that Xinlitai, CSPC Ouyi Pharmaceutical Co.

Claim 1 maintained in effect (mainly protecting 2.

This decision is equivalent to allowing Novartis to basically keep the crystal form patent of sacubitril valsartan sodium 2.

Although Novartis has achieved partial victory in the patent offensive and defensive battles with three domestic generic drug giants, as pointed out in the previous article, the patent challenges initiated by these three generic drug giants are just head-on battles on the battlefield.

Nanjing Yixinhe (Nanjing Fangshenghe Subsidiary) Filing of Trihydrate API

Entresto is a complex formed by the combination of sacubitril, valsartan, sodium ions and water molecules in a specific molar ratio.

With an announcement issued by Nanjing Fangsheng and the official WeChat on July 15, the obstacle of composition patents has been cleared

Judging from the above news, after lawyer Dai Jinliang challenged Entresto’s core patent composition in April 2017 and succeeded, the patentee appealed to the National Intellectual Property Court, and the Supreme People’s Court upheld the original judgment, which declared Entresto’s portfolio Material patents have been breached in China.

The development of new drugs in the field of heart failure is relatively slow.

Entresto has also been approved for the treatment of heart failure in China and is included in the 2020 National Medical Insurance List